Vericel (VCEL) Non-Current Assets (2010 - 2026)
Vericel (VCEL) reported Non-Current Assets of $241.6 million for Q1 2026, up 6.44% on a YoY basis from $226.9 million in Q1 2025, and little changed sequentially from $240.5 million in Q4 2025.
Vericel (VCEL) Non-Current Assets (2010 - 2026) Analysis & Trends
Vericel (VCEL) has 17 years of Non-Current Assets data on file, last reported at $241.6 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 6.44% year-over-year to $241.6 million; the trailing twelve-month figure through Mar 2026 stood at $944.4 million (up 14.31% YoY), and the FY2025 full-year result was $240.5 million, up 9.36% from the prior year.
- Non-Current Assets held at $241.6 million in Q1 2026, from $240.5 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $241.6 million in Q1 2026 to a low of $81.6 million in Q3 2022.
- A 5-year average of $163.5 million and a median of $166.9 million in 2024 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets fell 0.97% in 2023 and soared 90.68% in 2024, its largest moves.
- Tracing VCEL's Non-Current Assets over 5 years: stood at $86.1 million in 2022, then surged by 71.85% to $148.0 million in 2023, then soared by 48.59% to $219.9 million in 2024, then increased by 9.36% to $240.5 million in 2025, then increased by 0.43% to $241.6 million in 2026.
- Business Quant data shows VCEL's Non-Current Assets at $241.6 million in Q1 2026, $240.5 million in Q4 2025, and $231.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn | 241.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 241.56 Mn |
| Dec 31, 2025 | 240.53 Mn |
| Sep 30, 2025 | 231.31 Mn |
| Jun 30, 2025 | 231.03 Mn |
| Mar 31, 2025 | 226.95 Mn |
| Dec 31, 2024 | 219.95 Mn |
| Sep 30, 2024 | 199.89 Mn |
| Jun 30, 2024 | 179.45 Mn |
| Mar 31, 2024 | 166.94 Mn |
| Dec 31, 2023 | 148.03 Mn |
| Sep 30, 2023 | 131.91 Mn |
| Jun 30, 2023 | 127.84 Mn |
| Mar 31, 2023 | 87.55 Mn |
| Dec 31, 2022 | 86.14 Mn |
| Sep 30, 2022 | 81.64 Mn |
| Jun 30, 2022 | 89.72 Mn |
| Mar 31, 2022 | 88.41 Mn |
| Dec 31, 2021 | 85.24 Mn |
| Sep 30, 2021 | 79.20 Mn |
| Jun 30, 2021 | 83.43 Mn |